ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date

Monday, October 22, 2018

9:00AM-11:00AM
Abstract Number: 1772
Apremilast in Refractory Oral and/or Genital Ulcers in Behçet’s Disease. Multicenter Study of 37 Cases
Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 1481
Are ACPA Associated with More Bone Loss over Time in Patients with RA?
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis
9:00AM-11:00AM
Abstract Number: 1188
Are Residents Choosing Wisely? Analysis of Adherence to Recommendations of Ordering Anti-Nuclear Antibody Testing in an Internal Medicine Residency Primary Care Clinic
Health Services Research Poster II – ACR/ARHP
9:00AM-11:00AM
Abstract Number: 1065
Artesunate Can Synergize with Methotrexate on Inhibiting Migration and Invasion of Fibroblast-like Synoviocytes from Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Etiology and Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 1622
ASAS Consensus on Spanish Nomenclature for Spondyloarthritis
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies
9:00AM-11:00AM
Abstract Number: 1399
Assessing a Conceptual Framework of Quality of Life in a Cutaneous Lupus Erythematosus Population
Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes
9:00AM-11:00AM
Abstract Number: 1366
Assessment of Health-Related Quality of Life in a 52-Week, Phase 2, Randomized, Controlled Trial of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Treatment of Knee Osteoarthritis
Osteoarthritis – Clinical Poster II
9:00AM-11:00AM
Abstract Number: 1627
Assessment of Myocardial Dysfunction Using Speckle Tracking Echocardiography in Patients with Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies
9:00AM-11:00AM
Abstract Number: 1803
Assessment of Severity and Risk Factors of Post-Thrombotic Syndrome in Vascular Behçet Disease: Muticentered Retrospective Study
Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 1268
Assessment of the Persistence of Crystals Under Polarised Light Microscopy in Stored Synovial Fluid Samples
Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I
9:00AM-11:00AM
Abstract Number: 1405
Assessment of the Psychometric Properties of Patient-Reported Outcomes of Depression in SLE
Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes
9:00AM-11:00AM
Abstract Number: 1501
Assessment of Treatment Response Using the Multi-Biomarker Disease Activity Score in Rheumatoid Arthritis Patients Initiating Methotrexate
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis
9:00AM-11:00AM
Abstract Number: 1410
Assessment of Work Outcomes with Truncation from Job Loss in an Arthritis Randomized Clinical Trial
Patient Outcomes, Preferences, and Attitudes Poster I – ARHP
9:00AM-11:00AM
Abstract Number: 1087
Association between Cigarette Smoking and Systemic Lupus Erythematosus – a Bayesian Multivariate Meta-Analysis of Case-Control and Cohort Studies
Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 1169
Association between Depressive Symptom Subtypes and Disease Severity in Knee Osteoarthritis
Epidemiology and Public Health Poster II – ARHP
  • «Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology